NRx Pharmaceuticals Inc. (NRXP)
undefined
undefined%
At close: undefined
1.20
0.00%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.

Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior.

The company was founded in 2015 and is based in Wilmington, Delaware.

NRx Pharmaceuticals Inc.
NRx Pharmaceuticals Inc. logo
Country United States
IPO Date Dec 4, 2017
Industry Biotechnology
Sector Healthcare
Employees 2
CEO Dr. Jonathan C. Javitt M.D., M.P.H.

Contact Details

Address:
1201 Orange Street
Wilmington, Delaware
United States
Website https://www.nrxpharma.com

Stock Details

Ticker Symbol NRXP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001719406
CUSIP Number 089482103
ISIN Number US6294441000
Employer ID 82-2844431
SIC Code 2834

Key Executives

Name Position
Dr. Jonathan C. Javitt M.D., M.P.H. Co-Founder, Chief Scientist Officer, Chairman & Interim Chief Executive Officer
Matthew Patrick Duffy Chief Business Officer & Co-Chief Executive Officer of Hope Therapeutics
Richard Clavano Narido Chief Financial Officer & Treasurer
Dr. Philip T. Lavin Ph.D. Chief Methodologist
Dr. Riccardo Panicucci Ph.D. Chief Manufacturing & Technology Officer
Suzanne Messere Investor Relations

Latest SEC Filings

Date Type Title
Nov 22, 2024 3 Filing
Nov 20, 2024 8-K Current Report
Nov 15, 2024 8-K Current Report
Nov 14, 2024 10-Q Quarterly Report
Nov 14, 2024 S-1 Filing
Oct 31, 2024 8-K Current Report
Oct 15, 2024 8-K Current Report
Oct 11, 2024 8-K Current Report
Sep 05, 2024 DEF 14A Filing
Aug 27, 2024 PRE 14A Filing